SAM
TXMD icon

Smartleaf Asset Management’s TherapeuticsMD TXMD Stock Holding History

Smartleaf Asset Management’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.2K Hold
601
– – ﹤0.01% 3083
2025
Q4 		$986 Buy
+601
New +$869 ﹤0.01% 3162

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Smartleaf Asset Management's TXMD Position: Q1 2026 in Review

Smartleaf Asset Management held its TherapeuticsMD (TXMD) position steady in Q1 2026 at 601 shares worth $1.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3083.

Smartleaf Asset Management first reported a position in TXMD in Q4 2025 and has held it in 2 quarters since. 49 funds tracked by Wall St. Rank hold TXMD as of Q1 2026.

  • Smartleaf Asset Management held 601 shares of TherapeuticsMD worth $1.2K as of Q1 2026.
  • Smartleaf Asset Management left its TherapeuticsMD share count unchanged in Q1 2026.
  • TherapeuticsMD made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q1 2026, its #3083 holding.
  • Smartleaf Asset Management first reported a position in TherapeuticsMD in Q4 2025 and has held it in 2 quarters since.
  • 49 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2026.

Based on Smartleaf Asset Management's 13F filing for Q1 2026, filed 15 May 2026.